An updated reappraisal of dupilumab in children and adolescents with moderate–severe atopic dermatitis DOI
Giorgio Ciprandi, Amelia Licari,

Maria Angela Tosca

et al.

Pediatric Allergy and Immunology, Journal Year: 2024, Volume and Issue: 35(6)

Published: June 1, 2024

Abstract Atopic dermatitis (AD) is still a demanding challenge in clinical practice. Type 2 inflammation the most common inflammatory pathway children and adolescents with AD. Anti‐inflammatory drugs, mainly corticosteroids (CS) immunomodulant agents are primary therapeutic approach to dampening type inflammation. However, AD patients may require long‐term high CS doses or drug combinations possibly significant adverse effects achieve maintain disease control. In this regard, advent of biologics constituted breakthrough managing condition. Dupilumab monoclonal antibody directed against IL‐4 receptor α‐subunit (IL‐4Rα), antagonizing both IL‐13 approved for pediatric severe This review presents discusses recent published studies on dupilumab There convincing evidence that safe effective It can reduce skin lesions associated itching, need additional medications, improve control quality life. thorough diagnostic mandatory, especially considering different phenotypes. The ideal eligible candidate child adolescent requiring systemic treatment because manifestations impaired

Language: Английский

An updated reappraisal of dupilumab in children and adolescents with moderate–severe atopic dermatitis DOI
Giorgio Ciprandi, Amelia Licari,

Maria Angela Tosca

et al.

Pediatric Allergy and Immunology, Journal Year: 2024, Volume and Issue: 35(6)

Published: June 1, 2024

Abstract Atopic dermatitis (AD) is still a demanding challenge in clinical practice. Type 2 inflammation the most common inflammatory pathway children and adolescents with AD. Anti‐inflammatory drugs, mainly corticosteroids (CS) immunomodulant agents are primary therapeutic approach to dampening type inflammation. However, AD patients may require long‐term high CS doses or drug combinations possibly significant adverse effects achieve maintain disease control. In this regard, advent of biologics constituted breakthrough managing condition. Dupilumab monoclonal antibody directed against IL‐4 receptor α‐subunit (IL‐4Rα), antagonizing both IL‐13 approved for pediatric severe This review presents discusses recent published studies on dupilumab There convincing evidence that safe effective It can reduce skin lesions associated itching, need additional medications, improve control quality life. thorough diagnostic mandatory, especially considering different phenotypes. The ideal eligible candidate child adolescent requiring systemic treatment because manifestations impaired

Language: Английский

Citations

2